Cargando…

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

Parkinson’s disease (PD) is a prevalent neurodegenerative disease with no approved disease-modifying therapies. Multiplications, mutations, and single nucleotide polymorphisms in the SNCA gene, encoding α-synuclein (aSyn) protein, either cause or increase risk for PD. Intracellular accumulations of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cole, Tracy A., Zhao, Hien, Collier, Timothy J., Sandoval, Ivette, Sortwell, Caryl E., Steece-Collier, Kathy, Daley, Brian F., Booms, Alix, Lipton, Jack, Welch, Mackenzie, Berman, Melissa, Jandreski, Luke, Graham, Danielle, Weihofen, Andreas, Celano, Stephanie, Schulz, Emily, Cole-Strauss, Allyson, Luna, Esteban, Quach, Duc, Mohan, Apoorva, Bennett, C. Frank, Swayze, Eric E., Kordasiewicz, Holly B., Luk, Kelvin C., Paumier, Katrina L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021121/ https://www.ncbi.nlm.nih.gov/pubmed/33682798 http://dx.doi.org/10.1172/jci.insight.135633

Ejemplares similares

High-Frequency Stimulation of the Rat Entopeduncular Nucleus Does Not Provide Functional or Morphological Neuroprotection from 6-Hydroxydopamine
por: Fischer, D. Luke, et al.
Publicado: (2015)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2017)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

Cell therapy for Parkinson's disease: Why it doesn't work every time
por: Collier, Timothy J., et al.
Publicado: (2019)

The Longitudinal Transcriptomic Response of the Substantia Nigra to Intrastriatal 6-Hydroxydopamine Reveals Significant Upregulation of Regeneration-Associated Genes
por: Kanaan, Nicholas M., et al.
Publicado: (2015)

Impact of age and vector construct on striatal and nigral transgene expression
por: Polinski, Nicole K, et al.
Publicado: (2016)

Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia
por: Steece‐Collier, Kathy, et al.
Publicado: (2019)

Sonic Hedgehog Controls the Phenotypic Fate and Therapeutic Efficacy of Grafted Neural Precursor Cells in a Model of Nigrostriatal Neurodegeneration
por: Madhavan, Lalitha, et al.
Publicado: (2015)

Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression
por: Fischer, D. Luke, et al.
Publicado: (2017)

Downregulation of striatal Ca(V)1.3 inhibits the escalation of levodopa-induced dyskinesia in male and female parkinsonian rats of advanced age
por: Caulfield, Margaret E., et al.
Publicado: (2023)

Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS
por: Miller, Kathryn M., et al.
Publicado: (2021)

BDNF rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's disease
por: Fischer, D. Luke, et al.
Publicado: (2022)

The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats
por: Mercado, Natosha M., et al.
Publicado: (2020)

An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement
por: Poplawski, Shane G., et al.
Publicado: (2020)

Antisense oligonucleotides extend survival of prion-infected mice
por: Raymond, Gregory J., et al.
Publicado: (2019)

The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration
por: Jafar-nejad, Paymaan, et al.
Publicado: (2020)

Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides
por: Reidenbach, Andrew G., et al.
Publicado: (2019)

Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates
por: Collier, Timothy J., et al.
Publicado: (2016)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

A single-cell map of antisense oligonucleotide activity in the brain
por: Mortberg, Meredith A, et al.
Publicado: (2023)

A single-cell map of antisense oligonucleotide activity in the brain
por: Mortberg, Meredith A, et al.
Publicado: (2023)

Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system
por: Sullivan, Jenna M., et al.
Publicado: (2020)

Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
por: Østergaard, Michael E., et al.
Publicado: (2013)

Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein
por: Patterson, Joseph R., et al.
Publicado: (2022)

Repairing the Aged Parkinsonian Striatum: Lessons from the Lab and Clinic
por: Mercado, Natosha M, et al.
Publicado: (2016)

Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment
por: O’Callaghan, Brennon, et al.
Publicado: (2020)

Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity
por: Benskey, Matthew J., et al.
Publicado: (2018)

Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice
por: Chappell, Alfred E, et al.
Publicado: (2020)

New Frontiers in Neurodegeneration and Regeneration Associated with Brain-Derived Neurotrophic Factor and the rs6265 Single Nucleotide Polymorphism
por: Szarowicz, Carlye A., et al.
Publicado: (2022)

Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
por: Skotte, Niels H., et al.
Publicado: (2014)

Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides
por: Østergaard, Michael E., et al.
Publicado: (2017)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models
por: Moore, Lauren R., et al.
Publicado: (2017)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
por: Prakash, Thazha P, et al.
Publicado: (2019)

Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
por: Duffy, Megan F., et al.
Publicado: (2018)

Behavioral and Biochemical Assessment of Monoaminergic Neural Transplants to Rat Frontal Neocortex
por: Sortwell, Caryl E., et al.
Publicado: (1992)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9375o8i8edie4gpua10mau6ack